Replimune's drug for advanced skin cancer fails to win FDA nod again - Reuters
Replimune's drug for advanced skin cancer fails to win FDA nod again Reuters
Coverage by Political Leaning
See how different sides of the spectrum reported this story
Notable Quotes
"the company has no choice but to eliminate jobs and substantially scale back its U.S.-based manufacturing operations as a result of the decision."
— Sushil Patel , Executive
"decision on Tudriqev makes 'one less competitor' in the near-term for Iovance’s Amtagvi."
— Andrew Tsai , Executive
"the decision on Tudriqev makes 'one less competitor' in the near-term for Iovance’s Amtagvi."
— Andrew Tsai , Executive
Key People
Locations
Tags
All Coverage
<a href="https://news.google.com/rss/articles/CBMiswFBVV95cUxQV0xhbE5EbkRDa2l2OEdTdkhHRzlZU1cwdUM4bWt6ZGVTTWNIeFFUdHhDaW9SOHBiM3A3eV9VVTZoNXlRM0pNSk5adXJ1Vkw1SDZqSWI5aGlfT3B1VThsV21acFBVUU1RTE9oZXNSbHRMUlZTSzhNTGdXQTJELUgycm1QM0d5cGdQdlNicURjZEZ5LXVxa2t6MWh0aEI2N1o0UVM1X2VxMDAtb0t1T0pzSFdNTQ?oc=5" target="_blank">Replimune's drug for advanced skin cancer fails to win FDA nod again</a> <font color="#6f6f6f">Reuters</font>
The FDA declined to approve Replimune's RP1 drug for advanced skin cancer, citing insufficient data from studies, marking the second consecutive setback for the company.
The FDA declined to approve Replimune's RP1 drug for advanced skin cancer, citing insufficient data from studies, marking the second consecutive setback for the company.
The FDA declined to approve Replimune's RP1 drug for advanced skin cancer, citing insufficient data from studies, marking the second consecutive setback for the company.
The FDA declined to approve Replimune's RP1 drug for advanced skin cancer, citing insufficient data from studies, marking the second consecutive setback for the company.
The FDA declined to approve Replimune's RP1 drug for advanced skin cancer, citing insufficient data from studies, marking the second consecutive setback for the company.
Similar Stories
Related coverage based on topic and tags
Revolution's lifesaving pancreatic cancer drug wins speedy FDA approval - Reuters
Revolution's lifesaving pancreatic cancer drug wins speedy FDA approval Reuters
August 26, 2026 at 06:18 PMSuccess after a century of failures: Inside Moderna and Merck's cancer vaccine breakthrough - Reuters
Success after a century of failures: Inside Moderna and Merck's cancer vaccine breakthrough Reuters
August 28, 2026 at 11:32 AMGSK scores regulatory wins for chronic hepatitis B drug, cancer therapy - Reuters
GSK scores regulatory wins for chronic hepatitis B drug, cancer therapy Reuters
August 24, 2026 at 07:11 AMUS FDA approves Roivant-Priovant's skin and muscle disease drug - Reuters
US FDA approves Roivant-Priovant's skin and muscle disease drug Reuters
August 27, 2026 at 10:42 PMUS FDA approves Takeda, Protagonist's drug for rare blood cancer - Reuters
US FDA approves Takeda, Protagonist's drug for rare blood cancer Reuters
August 28, 2026 at 10:16 PMAstraZeneca-Amgen asthma drug succeeds in late-stage oesophagus disease trial - Reuters
AstraZeneca-Amgen asthma drug succeeds in late-stage oesophagus disease trial Reuters
August 27, 2026 at 06:10 AM